Literature DB >> 15054806

Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes.

Hirohito Suzuki1, Naoyuki Katayama, Yasushi Ikuta, Katsumi Mukai, Atsushi Fujieda, Hidetsugu Mitani, Hiroto Araki, Hiroyuki Miyashita, Natsuki Hoshino, Hiroyoshi Nishikawa, Kazuhiro Nishii, Nobuyuki Minami, Hiroshi Shiku.   

Abstract

We examined the actions of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) on human monocytes, using a serum-free culture system. GM-CSF and IL-3 did not promote the differentiation of monocytes into macrophages but rather into cells with a phenotype compatible with that of immature dendritic cells (DCs). The addition of fetal bovine serum to serum-free cultures with GM-CSF or IL-3 restored the differentiation of monocytes into macrophages. Cells generated with GM-CSF or IL-3 elicited phagocytic activity. Cells generated in the presence of GM-CSF or IL-3, followed by the addition of tumor necrosis factor-alpha, displayed a phenotype of mature DCs, and primed and stimulated immunogenic peptide-specific T lymphocytes. Surprisingly, GM-CSF and IL-3 inhibited macrophage colony-stimulating factor (M-CSF)-dependent differentiation of monocytes into macrophages and induced differentiation into immature DCs. We asked if the inhibition of M-CSF-dependent differentiation into macrophages by GM-CSF or IL-3 was associated with the expression of M-CSF receptors (M-CSFR). GM-CSF or IL-3 down-regulated the expression of M-CSFR. These data demonstrate that GM-CSF and IL-3 primarily support the differentiation of monocytes into DCs and inhibit M-CSF-dependent differentiation into macrophages by suppressing the expression of M-CSFR, thereby promoting differentiation into DCs. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15054806     DOI: 10.1002/ajh.20010

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

1.  sRAGE induces human monocyte survival and differentiation.

Authors:  Yijie Wang; Hongmei Wang; Melissa G Piper; Sara McMaken; Xiaokui Mo; Judy Opalek; Ann Marie Schmidt; Clay B Marsh
Journal:  J Immunol       Date:  2010-06-23       Impact factor: 5.422

2.  Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption.

Authors:  Morten A Karsdal; Kim Henriksen; Mette G Sørensen; Jeppe Gram; Sophie Schaller; Morten H Dziegiel; Anne-Marie Heegaard; Palle Christophersen; Thomas J Martin; Claus Christiansen; Jens Bollerslev
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

3.  Peripheral blood monocytes can differentiate into efficient insulin-producing cells in vitro.

Authors:  A Kyventidis; G Tzimagiorgis; T Didangelos
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

4.  5-Lipoxygenase inhibitors potentiate 1alpha,25-dihydroxyvitamin D3-induced monocytic differentiation by activating p38 MAPK pathway.

Authors:  Lenka Stixová; Jirina Procházková; Karel Soucek; Jirina Hofmanová; Alois Kozubík
Journal:  Mol Cell Biochem       Date:  2009-05-05       Impact factor: 3.396

Review 5.  GM-CSF-Dependent Inflammatory Pathways.

Authors:  John A Hamilton
Journal:  Front Immunol       Date:  2019-09-04       Impact factor: 7.561

6.  GM-CSF in inflammation.

Authors:  John A Hamilton
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

7.  Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial.

Authors:  Alexandra M Adams; Elizabeth L Carpenter; Guy T Clifton; Timothy J Vreeland; Robert C Chick; Anne E O'Shea; Patrick M McCarthy; Phillip M Kemp Bohan; Annelies T Hickerson; Franklin A Valdera; Ankur Tiwari; Diane F Hale; John R Hyngstrom; Adam C Berger; James W Jakub; Jeffrey J Sussman; Montaser F Shaheen; Xianzhong Yu; Thomas E Wagner; Mark B Faries; George E Peoples
Journal:  Cancer Immunol Immunother       Date:  2022-09-01       Impact factor: 6.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.